Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(R)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL, also known as (2R)-1-Boc-2-(hydroxymethyl)azetidine, is a chemical compound with a unique structure that has found applications in the pharmaceutical industry. It is characterized by its tert-butoxycarbonyl (Boc) group and azetidine ring, which contribute to its potential uses in drug development and synthesis.

161511-90-6

Post Buying Request

161511-90-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

161511-90-6 Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly for the development of oral analgesics. Its unique structure allows for efficient asymmetric synthesis, which is crucial in creating effective and selective pain-relieving medications.
Used in Pain Management Research:
In the field of pain management, (R)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL has been utilized to study the structure-activity relationship of (azetidinylmethoxy)chloropyridine derivatives. This research helps in understanding the molecular interactions and mechanisms behind the analgesic effects of these compounds, ultimately leading to the development of more potent and safer pain-relieving drugs.

Check Digit Verification of cas no

The CAS Registry Mumber 161511-90-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,1,5,1 and 1 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 161511-90:
(8*1)+(7*6)+(6*1)+(5*5)+(4*1)+(3*1)+(2*9)+(1*0)=106
106 % 10 = 6
So 161511-90-6 is a valid CAS Registry Number.

161511-90-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (B2174)  (R)-1-(tert-Butoxycarbonyl)-2-azetidinemethanol  >98.0%(GC)

  • 161511-90-6

  • 100mg

  • 3,100.00CNY

  • Detail
  • TCI America

  • (B2174)  (R)-1-(tert-Butoxycarbonyl)-2-azetidinemethanol  >98.0%(GC)

  • 161511-90-6

  • 1g

  • 11,000.00CNY

  • Detail

161511-90-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name (R)-1-Boc-2-Azetidinemethanol

1.2 Other means of identification

Product number -
Other names (R)-1-Boc-2-azetidinemethanol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:161511-90-6 SDS

161511-90-6Relevant articles and documents

Two Scalable Syntheses of (S)-2-Methylazetidine

Dowling, Matthew S.,Fernando, Dilinie P.,Hou, Jie,Liu, Bo,Smith, Aaron C.

, p. 3031 - 3036 (2016)

Two orthogonal routes for preparing (S)-2-methylazetidine as a bench stable, crystalline (R)-(-)-CSA salt are presented. One route features the in situ generation and cyclization of a 1,3-bis-triflate to form the azetidine ring, while the second route inv

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase

Angst, Daniela,Gessier, Fran?ois,Janser, Philipp,Vulpetti, Anna,W?lchli, Rudolf,Beerli, Christian,Littlewood-Evans, Amanda,Dawson, Janet,Nuesslein-Hildesheim, Barbara,Wieczorek, Grazyna,Gutmann, Sascha,Scheufler, Clemens,Hinniger, Alexandra,Zimmerlin, Alfred,Funhoff, Enrico G.,Pulz, Robert,Cenni, Bruno

supporting information, p. 5102 - 5118 (2020/06/10)

Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren's syndrome.

CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS

-

Page/Page column 79, (2019/01/08)

A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode

Jurica, Elizabeth A.,Wu, Ximao,Williams, Kristin N.,Hernandez, Andres S.,Nirschl, David S.,Rampulla, Richard A.,Mathur, Arvind,Zhou, Min,Cao, Gary,Xie, Chunshan,Jacob, Biji,Cai, Hong,Wang, Tao,Murphy, Brian J.,Liu, Heng,Xu, Carrie,Kunselman, Lori K.,Hicks, Michael B.,Sun, Qin,Schnur, Dora M.,Sitkoff, Doree F.,Dierks, Elizabeth A.,Apedo, Atsu,Moore, Douglas B.,Foster, Kimberly A.,Cvijic, Mary Ellen,Panemangalore, Reshma,Flynn, Neil A.,Maxwell, Brad D.,Hong, Yang,Tian, Yuan,Wilkes, Jason J.,Zinker, Bradley A.,Whaley, Jean M.,Barrish, Joel C.,Robl, Jeffrey A.,Ewing, William R.,Ellsworth, Bruce A.

, p. 1417 - 1431 (2017/03/08)

A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic acid, a key pharmacophore for GPR40. Addition of a 4-cis-CF3 to the pyrrolidine improves the human GPR40 binding Ki and agonist efficacy. After further optimization, the discovery of a minor enantiomeric impurity with agonist activity led to the finding that enantiomers (R,R)-68 and (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand. Compound (R,R)-68 activates both Gq-coupled intracellular Ca2+ flux and Gs-coupled cAMP accumulation. This signaling bias results in a dual mechanism of action for compound (R,R)-68, demonstrating glucose-dependent insulin and GLP-1 secretion in vitro. In vivo, compound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge, encouraging further development of the series.

Substituted Disulfonamide Compounds

-

Page/Page column 37, (2010/06/22)

Substituted disulfonamide compounds corresponding to formula I: In which R1, R2, R3, R4a, R4b, R5a, R5b, R8, R9a, R9b, R10, R11, a, b, s, t and A have defined meanings, pharmaceutical compositions containing one or more such compounds, processes for preparing such compounds, and a method of using such compounds for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin receptor 1 (BR1).

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

-

Page/Page column 257-258, (2008/06/13)

Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.

3-Pyridyl enantiomers and their use as analgesics

-

, (2008/06/13)

The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: STR1 or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release

-

, (2008/06/13)

Novel heterocyclic ether compounds of the formula: STR1 wherein n, *, R1, R2, R3 and y are specifically defined, or pharmaceutically acceptable salts or prodrugs thereof, which are useful in selectively controlling neurotransmitter release; therapeutically-effective pharmaceutical compositions of these compounds; and use of said compositions to selectively control neurotransmitter release in mammals.

Efficient asymmetric synthesis of ABT-594; a potent, orally effective analgesic

Lynch, John K.,Holladay, Mark W.,Ryther, Keith B.,Bai, Hao,Hsiao, Chi-Nung,Morton, Howard E.,Dickman, Daniel A.,Arnold, William,King, Steven A.

, p. 2791 - 2794 (2007/10/03)

A concise asymmetric synthesis of (R)-2-chloro-5-(2- azetidinylmethoxy)pyridine (ABT-594) is presented in which the key intermediate t-butoxycarbonyl protected (2R)-azetidinylalcohol is obtained in three steps from the dibenzyl ester of D-aspartic acid in 44% yield and >99% ee.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 161511-90-6